Sage Therapeutics (NASDAQ:SAGE) stock drops as Bank of America issues an Underperform rating citing an end to Biogen's (BIIB) ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

As Sage Therapeutics Inc. contemplates its path forward after rejecting a buyout offer from Biogen, its top executive ...

Sage Therapeutics has left its view of ... like its 2023 purchase of Reata Pharma and its rare disease therapy Skyclarys (omaveloxolone) for $7.3 billion and last year's $1.1 billion takeover ...

BofA resumed coverage of Sage Therapeutics (SAGE) with an Underperform rating and $5 price target. The impact of Biogen’s (BIIB) unsolicited ...

In late 2024, Sage announced that it would abandon the MDD indication for Zurzuvae entirely. According to GlobalData’s Pharma Intelligence Center, Zurzuvae is forecast to generate $656m in sales ...

Sage Therapeutics (SAGE) announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the ...

https://www.tipranks.com/news/the-fly/medtronic-price-target-raised-to-93-from-89-at-truist Scotiabank lowered the firm’s price target on Sage Therapeutics (SAGE ...

Sage's share price had fallen 22% at the time of writing, while Biogen also slipped by around 1%. Neurotech's cell therapy gets FDA nod for eye disorder MacTe... Neurotech Pharma's cell therapy ...

SAGE), operates under the pharmaceutical preparations industry. The company’s headquarters are located at 55 Cambridge Parkway, Cambridge, Massachusetts. According to InvestingPro data ...

Growth and Promise of the Psychedelic Drugs Market Many psychedelic-focused pharmaceutical businesses are working to have ...